BACKGROUND In this superiority study, pemetrexed was compared with erlotinib in pre‐
treated patients with metastatic non–small cell lung cancer (NSCLC). METHODS Patients …

7519 Background: To compare the efficacy of MTA and ERL as second-line treatment of
patients with advanced/metastatic NSCLC. Methods: Pts were randomized either to MTA …

Introduction Pemetrexed and erlotinib have been approved as second-line monotherapy for
locally advanced or metastatic non-small cell lung cancer (NSCLC). This multicentre …

Background This randomised controlled phase 2 study compared pemetrexed and erlotinib
in combination with either agent alone in terms of efficacy and safety as second-line …

Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …

Purpose To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in
pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and …

Several drugs have been approved for the treatment of patients affected by advanced non-
small cell lung cancer (NSCLC) in progression after first line chemotherapy: Docetaxel …

Background/Aims: The efficacy and safety of pemetrexed, gefitinib, and erlotinib
administration in previously treated patients with non-small cell lung cancer (NSCLC) were …

Purpose: Platinum-based regimens represent the standard first-line treatment for non-small-
cell lung cancer (SNCLC). However, newer data have established a role for pemetrexed in …

Introduction Recent pivotal phase III studies in patients with advanced non-small cell lung
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …